Skip to main content

ActivX Biosciences Wins $155K SBIR for Toxicity Research

NEW YORK, Aug. 1-The chemical proteomics firm ActivX Biosciences won a $155,000 Small Business Innovation Research grant for its toxicology research program, the company said today.

 

The grant, awarded by the National Cancer Institute, will fund six months of research. ActivX plans to investigate proteins as markers for toxicity. After identifying a set of proteins associated with toxic response, ActivX will create profiles that can be used to evaluate compounds for pharmaceutical development.

 

This award is the company's first SBIR grant. ActivX intends to apply for a Phase II SBIR grant to extend this research.

 

ActivX is a privately held firm in La Jolla, Calif.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.